Literature DB >> 12493480

Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp.

A Laplante1, M Demeule, G F Murphy, R Béliveau.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12493480     DOI: 10.1016/s0041-1345(02)03658-8

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  5 in total

1.  North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.

Authors:  Jann N Sarkaria; Evanthia Galanis; Wenting Wu; Patrick J Peller; Caterina Giannini; Paul D Brown; Joon H Uhm; Steven McGraw; Kurt A Jaeckle; Jan C Buckner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-23       Impact factor: 7.038

Review 2.  Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS.

Authors:  Mwlod Ghareeb; Fatemeh Akhlaghi
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

3.  Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.

Authors:  Eiman Mukhtar; Vaqar Mustafa Adhami; Imtiaz Ahmad Siddiqui; Ajit Kumar Verma; Hasan Mukhtar
Journal:  Mol Cancer Ther       Date:  2016-10-07       Impact factor: 6.261

4.  The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients.

Authors:  Finn Gustafsson; David Barth; Diego H Delgado; Meerna Nsouli; Jill Sheedy; Heather J Ross
Journal:  Eur J Clin Pharmacol       Date:  2009-05-21       Impact factor: 2.953

5.  Rapamycin-Loaded, CapryolTM 90 and Oleic Acid Mediated Nanoemulsions: Formulation Development, Characterization and Toxicity Assessment.

Authors:  Hamideh Sobhani; Parastoo Tarighi; Seyed Nasser Ostad; Alireza Shafaati; Nastaran Nafissi-Varcheh; Reza Aboofazeli
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.